Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
NCT05876364
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19
SARS-CoV-2
Interventions
BIOLOGICAL:
QTP104 1ug
BIOLOGICAL:
QTP104 5ug
BIOLOGICAL:
QTP104 25ug
Sponsor
Quratis Inc.